| __timestamp | Bristol-Myers Squibb Company | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 17986000 |
| Thursday, January 1, 2015 | 5001000000 | 32480000 |
| Friday, January 1, 2016 | 5002000000 | 68081000 |
| Sunday, January 1, 2017 | 4849000000 | 169906000 |
| Monday, January 1, 2018 | 4551000000 | 248932000 |
| Tuesday, January 1, 2019 | 4871000000 | 354100000 |
| Wednesday, January 1, 2020 | 7661000000 | 433300000 |
| Friday, January 1, 2021 | 7690000000 | 583300000 |
| Saturday, January 1, 2022 | 7814000000 | 752700000 |
| Sunday, January 1, 2023 | 7772000000 | 887600000 |
| Monday, January 1, 2024 | 8414000000 | 1007200000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. Over the past decade, Bristol-Myers Squibb Company and Neurocrine Biosciences, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bristol-Myers Squibb's SG&A costs have surged by approximately 36%, peaking in 2022. This reflects their aggressive expansion and marketing strategies. In contrast, Neurocrine Biosciences, though smaller, has seen a staggering increase of nearly 4,800% in SG&A expenses, highlighting their rapid growth and increased market presence. By 2023, Bristol-Myers Squibb's SG&A expenses were about 8.8 times higher than Neurocrine's, showcasing the scale difference between the two. These insights provide a window into the strategic priorities and market positioning of these pharmaceutical giants.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company
Breaking Down SG&A Expenses: Novartis AG vs Bristol-Myers Squibb Company
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Grifols, S.A.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bristol-Myers Squibb Company and Wave Life Sciences Ltd.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioMarin Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Neurocrine Biosciences, Inc. and Jazz Pharmaceuticals plc
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.